Phase 4 N=44 Conditioned Pharmacotherapeutic Effects in Hypertension
Hypertension
Primary: Mean Systolic Blood Pressure — 151.59; 152.64; 155.42; 151.74 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Phase 2 N=100 Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Percent Change in Plasma Triglycerides (Pharmacodynamic Population) — -20.9; -18.3 Percent Change from baseline
N/A N=55 Mechanisms of Action of Acetaminophen
Myocardial Infarction · Arthritis
Primary: Percent Change in Serum Thromboxane B2 — 97.0; 97.4; 98.3; 96.7 Percent inhibition of baseline — p=>0.05
N/A N=551 Pharmacological Management of Delirium
Delirium · Cognitive Impairment
Primary: Days Free of Delirium and Coma — 4; 5; 4; 5 days
Phase 1 N=7 Pharmacodynamic Evaluation of Intranasal Nalmefene
Pharmacodynamic
Primary: Change in Minute Ventilation — 3.432; 5.744 L/min — p=<0.0009
Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Phase 4 N=84 Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
Diabetic Autonomic Neuropathy
Primary: Change in E/I Ratio From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo — -0.02; -0.05 E/I ratio change — p=0.603
N/A N=179 Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care
Depression
Primary: Adherence to Antidepressant Medication — 78.4; 61.9; 60.1; 40.2 percentage of adherence patients
N/A N=38 Clinical Pharmacology of Electronic Cigarettes
Nicotine Dependence
Primary: Standardized Session: Mean CMax — 6.1; 20.2 ng/mL
Phase 2 N=66 Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
Early Phase 1 N=29 Neurophysiological and Acute Pharmacological Studies in FXS Patients
Fragile X Syndrome
Primary: Change in EEG Relative Gamma Power — 0.0024; -0.0077; -0.0039; 0.0019 percent of power in gamma frequencies
Phase 4 N=16 PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)
Anxiety Disorders
Primary: Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing
Phase 2 N=6 Pharmacological Activation of HMN for OSA
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep) — 20.8; 24.4; 18.8; 14 events/hour of sleep — p=>0.5
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
Phase 2 N=59 Pharmacokinetics of Advantage Arrest in Children
Dental Caries
Primary: Predicted Peak Serum Silver Concentration (Cmax) — 17.8 ng/ml
Phase 4 N=16 PharmacofMRI of Anxiolytic Medications (Pregabalin)
Anxiety Disorders
Primary: Effect of Pregabalin (Two Doses) Versus Placebo — 0.6; -0.1; 0.6 % signal change L amygdala + anticipn
Early Phase 1 N=6 Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Phase 4 N=40 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
Stable Coronary Artery Disease
Primary: Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading…
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
Phase 4 N=34 A Pharmacodynamic Study With Ticagrelor in African American Patients
Stable Coronary Artery Disease
Primary: Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading…
Early Phase 1 N=8 Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Interaction Drug Food
Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr
Phase 1 N=20 A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02
Phase 2 N=28 Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Primary Clinical Outcome PANSS Total Score (PANSSt) — 65.4; 55.6; 67.1; 49.8 score on a scale — p=0.28
Phase 1 N=36 Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
Healthy
Primary: Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) — 281.05; 485.48; 410.46 ng*h/mL
Phase 2 N=25 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Phase 4 N=33 The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans
Hypertension
Primary: Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment — 2.0; -3.4 mm Hg
Phase 2 N=16 Pharmacokinetics of Advantage Arrest
Dental Caries
Primary: Observed Fluoride Urinary Recovery — 1.29 mg
Phase 1 N=77 Pharmacodynamic Study of Cilostazol in Healthy Volunteers
Healthy
Primary: Ex-vivo Inhibition Of Platelet Aggregation (IPA) — 0.82; 1.21; 1.03; 4.42 ratio